

BENEFITS OF THE INNOVATIVE PAY-AS-YOU-GO MODEL FOR THE OMNIPOD DASH® INSULIN MANAGEMENT SYSTEM

Payment Model Aligns With the Consistent and Predictable Value of Omnipod DASH® in the US Healthcare System

Health plan benefits

- Avoid the high up-front costs and 4-year warranty of traditional pump payment model¹
- Reduced financial risk in case of patient attrition and health plan turnover compared with traditional payment model
- Customer preference for Omnipod® may also lower the risk of patient turnover¹
- Monthly billing provides simple, predictable budgeting for payers and plan sponsors²



Benefits for Omnipod® users

- Avoid the risk of high up-front costs and 4-year commitment associated with the traditional pump payment model¹
- Broad access means users are free to choose and stay with Omnipod® in the event their health insurance changes
- More consistent monthly copay for Pods similar to payment model for most other prescriptions²
- Omnipod® 5 will be launched at price parity with Omnipod DASH® to ensure broader market access and a more streamlined reimbursement decision
- Controller provided at no charge with the first order of Pods³

Broad Range of Health Plans Provides Pharmacy Access for Omnipod DASH®^{3†}



^{*}The 2019 patient choice survey by Seagrove Partners involved insulin pumps that were projected to be marketed in 2020. The 434 survey respondents included 230 insulin pump users (209 type 1 diabetes, 21 type 2 diabetes); 123 multiple daily injection users (78 type 1 diabetes, 45 type 2 diabetes); 30 type 2 diabetes long-acting injectable users only; and 51 type 2 diabetes non-insulin users.

[†]There are more than 4200 dispensing pharmacies nationwide for Omnipod DASH®, including CVS and Walgreens.³

PBM, pharmacy benefit manager.

Omnipod® 5 has not received 510(k) premarket clearance from the FDA and is not available for sale or use in the United States.

Pharmacy Directors, Medical Directors, and MDI Users View Pay-As-You-Go Model Favorably



In a survey of **86 pharmacy and medical directors**,

ONLY 15% OF PLANS

indicated they were **likely to keep paying up-front costs of approximately \$4500 for traditional insulin pumps** given the newer pay-as-you-go models¹




Respondents mainly stated **they were not seeing a return on investment on the up-front costs of pumps over a 2-year period¹**



Many respondents equated the pay-as-you-go model with **reduced risk¹**

In a separate survey, **78%** of MDI users (n=123) said the **pay-as-you-go model would increase their willingness to try Omnipod^{®1*}**



MDI, multiple daily injections.

*The 2019 patient choice survey by Seagrove Partners involved insulin pumps that were projected to be marketed in 2020. The 434 survey respondents included 230 insulin pump users (209 type 1 diabetes, 21 type 2 diabetes); 123 multiple daily injection users (78 type 1 diabetes, 45 type 2 diabetes); 30 type 2 diabetes long-acting injectable users only; and 51 type 2 diabetes non-insulin users.

References: **1.** Seagrove Partners syndicated services; 2020. The diabetes forum: 2020 insulin pump market primer. **2.** Omnipod from Insulet Corporation, pioneering the future of insulin delivery. MD Tech Review. Accessed January 8, 2021. <https://www.mdtechreview.com/vendor/omnipod-from-insulet-corporation-nasdaqpodd-pioneering-the-future-of-insulin-delivery-cid-41-mid-10.html> **3.** Data on file. Insulet Corporation.